Stonepine Capital Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Stonepine Capital Management’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-152,278	Closed	-$1.64M	–	25
2022 Q3	$1.64M	Hold	152,278	–	–	0.74%	17
2022 Q2	$1.83M	Buy	+152,278	New	+$2.46M	0.85%	19
2020 Q2	–	Sell	-380,948	Closed	-$3.65M	–	19
2020 Q1	$3.65M	Buy	380,948 +46,676	+14%	+$559K	3.86%	9
2019 Q4	$4.81M	Buy	334,272 +20,199	+6%	+$294K	3.36%	9
2019 Q3	$4.73M	Sell	314,073 -1,395	-0.4%	-$19.4K	4.59%	8
2019 Q2	$4.18M	Buy	315,468 +20,574	+7%	+$249K	2.88%	13
2019 Q1	$3.87M	Sell	294,894 -63,066	-18%	-$919K	2.23%	15
2018 Q4	$5.17M	Buy	357,960 +172,073	+93%	+$2.81M	4.54%	9
2018 Q3	$3.32M	Buy	+185,887	New	+$3.22M	1.94%	15

Other funds holding OPNT

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

ACA

Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NYLIM

New York Life Investment Management New York $11.8B AUM 23.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return

Stonepine Capital Management's OPNT Position: Q4 2022 in Review

Stonepine Capital Management sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2022, closing a stake of 152,278 shares — an estimated $1.64M sold.

Stonepine Capital Management first reported a position in OPNT in Q3 2018 and held it in 9 quarters. The position peaked at $5.17M in Q4 2018. 37 funds tracked by Wall St. Rank hold OPNT as of Q4 2022.

Stonepine Capital Management reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Stonepine Capital Management sold 152,278 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $1.64M.
Stonepine Capital Management first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 9 quarters.
Stonepine Capital Management's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $5.17M in Q4 2018.
37 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Stonepine Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.